Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Radiation Oncology
Would you offer radiation therapy to a patient with early stage breast cancer following chemotherapy in the setting of systemic bullous mastocytosis?
Related Questions
Are there any potential benefits to irradiating the partial breast with an MR-linac over conventional linac?
Would you offer reirradiation for a patient who had prior MammoSite PBI?
Would you consider omitting PMRT in cT3N0 triple negative breast cancer with a pCR?
What is your approach to a tumor bed boost in early stage breast cancer patients with micrometastasis?
When evaluating for PMRT in patients who did not receive neoadjuvant chemotherapy and are found to be pN0, do you utilize clinical T-staging, or pathologic T-staging?
What radiation would you offer for isolated nodal recurrence in a patient who received APBI for breast cancer about 2 years ago after ALND?
How do you approach breast RT in a patient with a recent history of ipsilateral thoracic irradiation?
Is a completion axillary dissection required for a patient with clinical N+ disease who had a complete clinical response in the axilla to neoadjuvant systemic therapy but is found to ypN+ disease on sentinel node biopsy?
When do you consider the addition of concurrent pembrolizumab to breast irradiation?
In the era of hypofractionation for breast cancer, how would you re-irradiate for these cases if recurrence develops years later?